{"url_path":"/sec/kalv/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1348911/0001193125-26-223976-index.html","accession_number":"0001193125-26-223976","cik":"0001348911","ticker":"KALV","issuer_name":"KalVista Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1348911/0001193125-26-223976-index.html","primary_entity_key":"0001348911","primary_entity_name":"KalVista Pharmaceuticals, Inc."},"word_count":60,"has_tables":true,"body_markdown":"Item 5. OTHER INFORMATION\n\n(c) Insider Trading Arrangements and Policies\n\nDuring the three months ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading agreement” or a “non-Rule 10b5-1 trading agreement” as each term is defined in Item 408(a) of Regulation S-K.\n\n24"}